OMERS ADMINISTRATION Corp Invests $505,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

OMERS ADMINISTRATION Corp purchased a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 37,900 shares of the company's stock, valued at approximately $505,000. OMERS ADMINISTRATION Corp owned 0.15% of Eton Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ETON. XTX Topco Ltd raised its holdings in shares of Eton Pharmaceuticals by 29.6% during the 4th quarter. XTX Topco Ltd now owns 14,655 shares of the company's stock valued at $195,000 after buying an additional 3,351 shares during the period. Tower Research Capital LLC TRC acquired a new stake in Eton Pharmaceuticals during the 4th quarter valued at $86,000. Jefferies Financial Group Inc. purchased a new stake in Eton Pharmaceuticals during the 4th quarter worth $133,000. Bank of America Corp DE increased its position in shares of Eton Pharmaceuticals by 5,422.4% during the fourth quarter. Bank of America Corp DE now owns 11,100 shares of the company's stock worth $148,000 after acquiring an additional 10,899 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Eton Pharmaceuticals in the fourth quarter worth about $147,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Price Performance

ETON traded up $0.01 during trading hours on Thursday, hitting $20.25. 345,879 shares of the stock were exchanged, compared to its average volume of 195,455. The stock has a market cap of $543.06 million, a price-to-earnings ratio of -92.05 and a beta of 1.22. The stock has a 50-day simple moving average of $15.11 and a 200-day simple moving average of $14.12. Eton Pharmaceuticals, Inc. has a 12 month low of $3.18 and a 12 month high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The business had revenue of $17.28 million during the quarter, compared to the consensus estimate of $14.33 million. Sell-side analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ETON. HC Wainwright restated a "buy" rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th. Craig Hallum upped their target price on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Finally, B. Riley reiterated a "buy" rating and issued a $26.00 price target (up from $24.00) on shares of Eton Pharmaceuticals in a research note on Friday, May 16th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.